zoledronic acid has been researched along with Spinal Fractures in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (12.86) | 29.6817 |
| 2010's | 33 (47.14) | 24.3611 |
| 2020's | 28 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, S; Liu, K; Shi, X; Tang, B; Wu, L; Zeng, H | 1 |
| Gao, P; Jiang, Y; Li, M; Wang, O; Xia, W; Xing, X; Yan, S; Zhang, Q; Zhang, Y | 1 |
| Pu, D; Xie, LL; Yu, H; Yuan, X | 1 |
| Balzarini, L; Berruti, A; Carrone, F; Cosentini, D; Farina, D; Lania, AG; Mazziotti, G; Pedersini, R; Pigni, S; Simoncini, EL; Torrisi, R; Vena, W; Zambelli, A | 1 |
| Liu, K; Lu, Q; Sun, W; Tan, G; Tang, J; Yu, D | 1 |
| Bastin, S; Bolland, MJ; Gamble, GD; Horne, AM; Mihov, B; Reid, IR | 1 |
| Huang, J; Li, P; Li, Y; Wu, X | 1 |
| Lane, JM; Levin, JE; Nieves, JW; Tutaworn, T; Wang, Z; Yoo, JE | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 1 |
| Chang, AB; Conwell, LS; Jeffery, TC | 1 |
| Choi, SS; Choung, YJ; Jeong, SJ; Kim, H; Lee, CH | 1 |
| Chang, YF; Cheng, TT; Huang, CF; Hwang, JS; Li, CC; Lu, TH; Shih, CA; Tai, TW; Tsai, YL; Wu, CH | 1 |
| Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR | 1 |
| Chen, LH; Ma, WJ; Wang, WY; You, RX | 1 |
| Kim, H; Lee, CH; Park, S; Sik Choi, S; Yoon Byun, S | 1 |
| Chang, Y; Huang, S; Ke, Y; Liang, C; Liang, G; Xiao, D; Zheng, X; Zhu, X; Zhuang, J | 1 |
| Aminnejad, R; Taheri, M | 1 |
| Chen, S; Li, C; Li, H; Wang, R; Wang, Y; Yue, L | 1 |
| Dedeyne, L; Dejaeger, M; Dupont, J; Gielen, E; Laurent, MR; Luyten, FP | 1 |
| Gao, Y; Hu, W; Shi, X; Song, Y; Wang, H; Xing, S; Zhang, G; Zhang, K | 1 |
| Huang, Y; Wu, D | 1 |
| Liu, SL; Luo, DM; Shen, XT; Xu, XY; Yuan, GD; Zhou, ZY | 1 |
| Aikeremu, D; Alimasi, W; Liu, Y; Lu, L; Nazierhan, S; Niyazi, W; Sun, Z; Wang, H; Xu, K | 1 |
| Jin, Y; Li, C; Lu, K; Shan, HQ; Yin, Y | 1 |
| Cai, B; Wang, F; Zhuang, M | 1 |
| Gong, H; Gu, J; Hao, Y; Hou, X; Li, K; Li, L; Lin, C; Wang, S; Xie, R; Yin, J; Zhang, Q | 1 |
| Kimura, T; Minowa, T; Mizushima, A; Takano, H; Uehara, Y; Watanabe, D; Watanabe, K; Yamashita, A; Yoshikawa, S | 1 |
| Ma, H; Sun, Y; Tan, M; Tang, X; Yang, F; Yi, P | 1 |
| Arosio, M; Cairoli, E; Chiodini, I; Eller-Vainicher, C; Grassi, G; Palmieri, S | 1 |
| Albert, SG; Reddy, S | 1 |
| Aeberli, D; Lehmann, T | 1 |
| Gan, F; Ge, Y; Liu, B; Yu, H | 1 |
| Djulbegovic, B; Kumar, A; Mhaskar, R; Miladinovic, B | 1 |
| Balasubramanian, A; Cooper, C; Cummings, SR; Feudjo, MT; Guo, H; Sprafka, JM; Watts, NB; Yusuf, AA; Zhou, J | 1 |
| Cheng, AY; Huang, ZF; Shi, C; Zhang, M | 1 |
| Huang, ZF; Liu, K; Xiao, SX; Xiong, W | 1 |
| Cai, Q; Xu, X; Zhang, J; Zhang, T; Zhao, D | 1 |
| Brasure, M; Butler, M; Ensrud, KE; Fink, HA; Forte, ML; MacDonald, R; Nelson, VA; Olson, CM; Rosebush, CE; Schousboe, JT; Taylor, BC; Ullman, K; Wilt, TJ | 1 |
| Bismarck, E; Dörsam, J; Ebert, T; Schmitz-Dräger, BJ; Weiss, C | 1 |
| Anitua, E; Begoña, L; Cobos, R; Orive, G; Serrano, AJ | 1 |
| Atkinson, C; Ball, J; D'Este, C; Delahunt, B; Denham, JW; Diamond, T; Duchesne, G; Gogna, NK; Joseph, D; Kautto, A; Kenny, L; Lamb, DS; Lynch, K; Matthews, J; McElduff, P; Moscato, P; Murray, J; Nowitz, M; Rowan, D; Smart, R; Spry, NA; Steigler, A; Tai, KH; Turner, S; Vimieiro, R; Woodfield, R | 1 |
| Chen, YC; Hsu, HT; Huang, KF; Li, HY; Tu, CW; Yang, SS | 1 |
| Reid, IR | 1 |
| Adler, RA; Bauer, DC; Camacho, PM; Clarke, BL; Clines, GA; Compston, JE; Drake, MT; Edwards, BJ; El-Hajj Fuleihan, G; Favus, MJ; Greenspan, SL; McKinney, R; Pignolo, RJ; Sellmeyer, DE | 1 |
| Chen, LH; Chen, WJ; Fu, TS; Lai, PL; Lin, TY; Niu, CC; Tsai, TT; Yang, SC | 1 |
| Fukunaga, M; Hagino, H; Ito, M; Kishimoto, H; Nakamura, T; Nakano, T; Ohashi, M; Ota, Y; Shiraki, M; Sone, T; Taguchi, A; Tanaka, S | 1 |
| Foster, JC; Go, RS; Grubbs, SS; Himelstein, AL; Khatcheressian, JL; Loprinzi, CL; Novotny, PJ; O'Connor, T; O'Mara, A; Qin, R; Roberts, JD; Seisler, DK; Shapiro, CL; Velasco, MR; Weckstein, D | 1 |
| Bell, JM; Beringer, T; Blackwood, B; Elliott, M; Hamilton, A; Quinlivan, R; Shields, MD; Tirupathi, S; Watters, J | 1 |
| Hagino, H; Moriwaki, K; Mouri, M | 1 |
| Hochberg, MC | 1 |
| Bouxsein, ML; Brouwers, JE; Rietbergen, Bv; Ruchelsman, M | 1 |
| Adachi, JD; Boonen, S; Colón-Emeric, CS; Eriksen, EF; Hu, H; Hyldstrup, L; Lavecchia, C; Lyles, KW; Magaziner, JS; Mesenbrink, P; Nordsletten, L; Pieper, CF; Recknor, C | 1 |
| Adami, S; Black, DM; Boonen, S; Cauley, JA; Cummings, SR; Delmas, PD; Eastell, R; Felsenberg, D; Lippuner, K; Mesenbrink, P; Palermo, L | 1 |
| Brendel, C; Hamann, C; Hofbauer, LC; Krüger, A; Neubauer, A; Ramaswamy, A; Schnabel, M | 1 |
| Black, DM; Boonen, S; Colón-Emeric, CS; Eastell, R; Eriksen, EF; Haentjens, P; Lyles, KW; Magaziner, JS; Mesenbrink, P | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Costa, L; Lipton, A | 1 |
| Van Poznak, C | 1 |
| Adachi, JD; Boonen, S; Bucci-Rechtweg, C; Colón-Emeric, CS; Eriksen, EF; Hyldstrup, L; Lyles, KW; Magaziner, JS; Mautalen, C; Moore, KA; Nordsletten, L; Pieper, CF; Recknor, C; Su, G | 1 |
| Hero, M; Mäkitie, O; Toiviainen-Salo, S; Vuorimies, I | 1 |
| Black, D; Boonen, S; Cauley, JA; Cummings, SR; Hadji, P; Man, Z; Mesenbrink, P; Palermo, L; Reid, IR | 1 |
| Black, DM; Bucci-Rechtweg, C; Burch, S; Palermo, L; Seeman, E; Wustrack, R | 1 |
| Bauer, DC; Black, DM; Boonen, S; Cosman, F; Eastell, R; Jacques, RM; Reid, IR | 1 |
| Beaujeux, R; Boujan, F; Boyer, P; Cebula, H; Froelich, S | 1 |
| Miller, PD | 1 |
| Antunez, O; Boonen, S; Brixen, K; Bucci-Rechtweg, C; Claessens, F; Dimai, HP; Eriksen, E; Hruska, J; Incera, E; Kaufman, JM; Langdahl, B; Lippuner, K; Lipschitz, S; Orwoll, E; Papanastasiou, P; Reginster, JY; Rizzoli, R; Russo, L; Su, G; Vanderschueren, D; Witvrouw, R; Zanchetta, J | 1 |
| Borges, CT; Jorgetti, V; Pereira, RM; Souza, SC | 1 |
| Wallace, DJ | 1 |
| Black, DM; Boonen, S; Caminis, J; Cauley, JA; Cosman, F; Cummings, SR; Delmas, PD; Eastell, R; Eriksen, EF; Hu, H; Hue, TF; Krasnow, J; Lakatos, P; Leung, PC; Man, Z; Mautalen, C; Mesenbrink, P; Reid, IR; Rosario-Jansen, T; Sellmeyer, D; Tong, K | 1 |
| Geusens, PP; Lems, WF | 1 |
18 review(s) available for zoledronic acid and Spinal Fractures
| Article | Year |
|---|---|
Percutaneous Vertebroplasty Combined with Zoledronic Acid in Treatment and Prevention of Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis of Comparative Studies.
Topics: Aged; Bone Density Conservation Agents; Combined Modality Therapy; Female; Fractures, Compression; Humans; Male; Middle Aged; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; Vertebroplasty; Zoledronic Acid | 2022 |
A review of the zoledronic acid combined with percutaneous vertebroplasty in the osteoporotic vertebral compression fracture.
Topics: Bone Diseases, Metabolic; Fractures, Compression; Humans; Lumbar Vertebrae; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2023 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female; Fractures, Bone; Humans; Musculoskeletal Pain; Osteoporosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2023 |
Risk factors for new vertebral compression fracture after kyphoplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study.
Topics: Calcium; Fractures, Compression; Humans; Kyphoplasty; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Risk Factors; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2022 |
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
Topics: Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Teriparatide; Zoledronic Acid | 2023 |
Effectiveness and safety of percutaneous kyphoplasty combined with zoledronic acid in treatment of osteoporotic vertebral compression fractures: a meta-analysis.
Topics: Bone Cements; Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Retrospective Studies; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2022 |
Clinical efficacy of zoledronic acid combined with percutaneous kyphoplasty in the prevention and treatment of osteoporotic vertebral compression fracture: A systematic review and meta-analysis.
Topics: Bone Density Conservation Agents; Humans; Kyphoplasty; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2021 |
Clinical Efficacy and Safety of Zoledronic Acid Combined with PVP/PKP in the Treatment of Osteoporotic Vertebral Compression Fracture: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2021 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Teriparatide; Zoledronic Acid | 2017 |
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2017 |
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Administration Schedule; Duration of Therapy; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2019 |
Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2013 |
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
Topics: Advisory Committees; Age Factors; Diphosphonates; Female; Femoral Fractures; Humans; Imidazoles; Male; Osteoporosis; Risk Factors; Sex Factors; Spinal Fractures; Zoledronic Acid | 2016 |
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
Topics: Adolescent; Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Calcium; Child; Child, Preschool; Diphosphonates; Humans; Imidazoles; Male; Muscular Dystrophy, Duchenne; Osteoporosis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Vibration; Vitamin D; Weight-Bearing; Zoledronic Acid | 2017 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
Rapid prevention of vertebral fractures associated with osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2005 |
18 trial(s) available for zoledronic acid and Spinal Fractures
| Article | Year |
|---|---|
Percutaneous kyphoplasty combined with zoledronic acid for the treatment of primary osteoporotic vertebral compression fracture: a prospective, multicenter study.
Topics: Bone Cements; Female; Fractures, Compression; Humans; Kyphoplasty; Male; Osteoporotic Fractures; Prospective Studies; Retrospective Studies; Spinal Fractures; Spine; Treatment Outcome; Zoledronic Acid | 2023 |
Zoledronate Reduces Height Loss Independently of Vertebral Fracture Occurrence in a Randomized Trial in Osteopenic Older Women.
Topics: Aged; Body Height; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Quality of Life; Spinal Fractures; Zoledronic Acid | 2022 |
Effect of Preoperative Zoledronic Acid Administration on Pain Intensity after Percutaneous Vertebroplasty for Osteoporotic Vertebral Compression Fractures.
Topics: Aged; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; Male; Middle Aged; Osteoporotic Fractures; Pain, Postoperative; Quality of Life; Spinal Fractures; Vertebroplasty; Zoledronic Acid | 2020 |
Efficacy of annual zoledronic acid in initial percutaneous kyphoplasty patients with osteoporotic vertebral compression fractures: a 3-year follow-up study.
Topics: Aged; Bone Cements; Follow-Up Studies; Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Prospective Studies; Retrospective Studies; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2021 |
Clinical Efficacy Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in the Treatment and Prevention of Osteoporotic Vertebral Compression Fractures.
Topics: Aged; Aged, 80 and over; Back Pain; Bone Density Conservation Agents; Combined Modality Therapy; Female; Follow-Up Studies; Fractures, Compression; Humans; Kyphoplasty; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2018 |
Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Combined Modality Therapy; Female; Fractures, Compression; Humans; Kyphoplasty; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prospective Studies; Recurrence; Spinal Fractures; Thoracic Vertebrae; Zoledronic Acid | 2019 |
Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced pr
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Australia; Bone Density; Bone Density Conservation Agents; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; New Zealand; Prostatic Neoplasms; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2014 |
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Japan; Male; Osteoporosis; Osteoporotic Fractures; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2017 |
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Prostatic Neoplasms; Sample Size; Spinal Cord Compression; Spinal Fractures; Zoledronic Acid | 2017 |
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis, Postmenopausal; Risk Factors; Spinal Fractures; Time Factors; Zoledronic Acid | 2009 |
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Health Status; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Quality of Life; Spinal Fractures; Surveys and Questionnaires; Zoledronic Acid | 2011 |
Zoledronic acid treatment in children with osteogenesis imperfecta.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Infant; Lumbar Vertebrae; Male; Osteogenesis Imperfecta; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2011 |
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.
Topics: Back Pain; Bed Rest; Bone Density Conservation Agents; Diphosphonates; Disabled Persons; Drug Administration Schedule; Female; Humans; Imidazoles; Multivariate Analysis; Prevalence; Probability; Risk Factors; Spinal Fractures; Zoledronic Acid | 2011 |
Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Female; Femur Neck; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prognosis; Spinal Fractures; Trauma Severity Indices; Zoledronic Acid | 2012 |
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hip; Humans; Imidazoles; Incidence; Osteoporosis, Postmenopausal; Placebos; Risk Factors; Spinal Fractures; Zoledronic Acid | 2012 |
Fracture risk and zoledronic acid therapy in men with osteoporosis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Humans; Hypogonadism; Imidazoles; Logistic Models; Male; Middle Aged; Osteoporosis; Risk; Spinal Fractures; Testosterone; Zoledronic Acid | 2012 |
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Incidence; Infusions, Intravenous; Osteoporosis, Postmenopausal; Risk; Spinal Fractures; Zoledronic Acid | 2007 |
[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis, Postmenopausal; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2007 |
34 other study(ies) available for zoledronic acid and Spinal Fractures
| Article | Year |
|---|---|
Clinical, Biochemical, Radiological, and Genetic Analyses of a Patient with VCP Gene Variant-Induced Paget's Disease of Bone.
Topics: Female; Fractures, Compression; Frontotemporal Dementia; Humans; Muscular Diseases; Mutation; Osteitis Deformans; Pain; Profilins; Spinal Fractures; Valosin Containing Protein; Zoledronic Acid | 2022 |
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Child; Child, Preschool; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Prospective Studies; Spinal Fractures; Zoledronic Acid | 2022 |
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Diphosphonates; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2023 |
Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter.
Topics: Bone Density Conservation Agents; Humans; Osteoporosis; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2023 |
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid | 2023 |
Risk factors for new vertebral compression fracture after vertebroplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study.
Topics: Bone Cements; Fractures, Compression; Humans; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Risk Factors; Spinal Fractures; Steroids; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2023 |
Therapeutic effect of percutaneous kyphoplasty combined with anti-osteoporosis drug on postmenopausal women with osteoporotic vertebral compression fracture and analysis of postoperative bone cement leakage risk factors: a retrospective cohort study.
Topics: Bone Cements; Bone Density Conservation Agents; Cohort Studies; Combined Modality Therapy; Female; Fractures, Compression; Humans; Kyphoplasty; Middle Aged; Osteoporosis; Osteoporotic Fractures; Postmenopause; Postoperative Complications; Retrospective Studies; Risk Assessment; Risk Factors; Spinal Fractures; Zoledronic Acid | 2019 |
Re: "Effectiveness Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in Treatment of Primary Osteoporotic Vertebral Compression Fractures".
Topics: Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2020 |
Effects of rosuvastatin and zoledronic acid in combination on the recovery of senile osteoporotic vertebral compression fracture following percutaneous vertebroplasty.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Bone Density; Case-Control Studies; Drug Therapy, Combination; Female; Fractures, Compression; Functional Status; Humans; Male; Middle Aged; Osteoporotic Fractures; Pain Management; Pain, Postoperative; Recurrence; Retrospective Studies; Rosuvastatin Calcium; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2020 |
Vertebral fractures after denosumab cessation.
Topics: Back Pain; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Diagnosis, Differential; Drug Substitution; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risk Adjustment; Secondary Prevention; Spinal Fractures; Thoracic Vertebrae; Withholding Treatment; Zoledronic Acid | 2020 |
[Clinical application of zoledronic acid combined with vitamin K2 in percutaneous vertebroplasty for multi-segment osteoporotic vertebral compression fractures].
Topics: Bone Cements; Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Retrospective Studies; Spinal Fractures; Treatment Outcome; Vertebroplasty; Vitamin K 2; Zoledronic Acid | 2020 |
[Treatment of severely osteoporotic vertebral compression fractures with the vertebral body stent system and percutanous kyphoplasty combined with zoledronic acid].
Topics: Aged; Aged, 80 and over; Bone Cements; Female; Fractures, Compression; Humans; Kyphoplasty; Male; Middle Aged; Osteoporotic Fractures; Retrospective Studies; Spinal Fractures; Stents; Treatment Outcome; Zoledronic Acid | 2020 |
Expression changes of IL-17 in zoledronic acid combined with PVP technology in the treatment of postmenopausal osteoporotic vertebral compression fracture and its predictive value of relapse.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; Infusions, Intravenous; Interleukin-17; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Recurrence; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2020 |
Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Comorbidity; Drug Administration Schedule; Humans; Japan; Kidney Function Tests; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Public Health Surveillance; Retrospective Studies; Risk Factors; Spinal Fractures; Zoledronic Acid | 2021 |
Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Spinal Fractures; Zoledronic Acid | 2021 |
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
Topics: Aged; Bone Density Conservation Agents; Denosumab; Drug Substitution; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2017 |
Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Denosumab; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Spinal Fractures; Teriparatide; United States; Zoledronic Acid | 2018 |
Percutaneous kyphoplasty combined with zoledronic acid infusion in the treatment of osteoporotic thoracolumbar fractures in the elderly.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Female; Fractures, Compression; Humans; Imidazoles; Infusions, Intravenous; Kyphoplasty; Lumbar Vertebrae; Male; Osteoporotic Fractures; Radiography; Recurrence; Retrospective Studies; Spinal Fractures; Thoracic Vertebrae; Vertebroplasty; Zoledronic Acid | 2018 |
Effectiveness Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in Treatment of Primary Osteoporotic Vertebral Compression Fractures.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Cohort Studies; Combined Modality Therapy; Female; Fractures, Compression; Humans; Kyphoplasty; Male; Middle Aged; Osteoporotic Fractures; Quality of Life; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2019 |
Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Diseases; Denosumab; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Life Expectancy; Male; Numbers Needed To Treat; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spinal Fractures; Time Factors; Treatment Outcome; Zoledronic Acid | 2013 |
Zoledronic acid infusion for lumbar interbody fusion in osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disability Evaluation; Female; Follow-Up Studies; Fractures, Compression; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Pedicle Screws; Retrospective Studies; Spinal Fractures; Spinal Fusion; Spondylolisthesis; Treatment Outcome; Zoledronic Acid | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Correlation between zoledronic acid infusion and repeat vertebroplasty surgery in osteoporotic patients.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Male; Osteoporosis; Reoperation; Retrospective Studies; Risk Factors; Sex Factors; Spinal Fractures; Taiwan; Vertebroplasty; Zoledronic Acid | 2016 |
Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Hip Fractures; Humans; Imidazoles; Injections, Intravenous; Japan; Models, Econometric; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality-Adjusted Life Years; Sensitivity and Specificity; Spinal Fractures; Zoledronic Acid | 2017 |
Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats.
Topics: Animals; Bone Density Conservation Agents; Compressive Strength; Diphosphonates; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Spinal Fractures; Spine; X-Ray Microtomography; Zoledronic Acid | 2009 |
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Topics: Aged; Aged, 80 and over; Body Mass Index; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Femur Neck; Hip Fractures; Humans; Imidazoles; Spinal Fractures; Zoledronic Acid | 2009 |
Multimodal therapy for vertebral involvement of systemic mastocytosis.
Topics: Adult; Back Pain; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Histamine; Humans; Hypotension; Imidazoles; Male; Mast Cells; Mastocytosis, Systemic; Osteoporosis; Postoperative Complications; Prednisolone; Pressure; Proto-Oncogene Proteins c-kit; Spinal Fractures; Spine; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2009 |
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Topics: Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Femoral Neck Fractures; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Medication Adherence; Osteoporosis; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2010 |
Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multicenter Studies as Topic; Pain; Pain Measurement; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
Predicting skeletal complications in metastatic breast cancer raises challenges.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Pain; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
[Giant cell tumor of the C2 colonized by an aneurismal bone cyst. Report of case].
Topics: Accidents, Home; Adult; Bone Cysts, Aneurysmal; Bone Density Conservation Agents; Bone Plates; Cervical Vertebrae; Diphosphonates; Embolization, Therapeutic; Fracture Fixation, Internal; Fractures, Spontaneous; Giant Cell Tumors; Humans; Imidazoles; Ligation; Magnetic Resonance Imaging; Male; Odontoid Process; Spinal Cord Compression; Spinal Fractures; Spinal Neoplasms; Spinal Stenosis; Tomography, X-Ray Computed; Torticollis; Vertebral Artery; Zoledronic Acid | 2012 |
Bone strength and surrogate markers: the first, second, and third fiddle.
Topics: Bone Density; Diphosphonates; Female; Hip; Humans; Imidazoles; Osteoporosis, Postmenopausal; Spinal Fractures; Zoledronic Acid | 2012 |
Zoledronic acid prevents fractures in men with osteoporosis.
Topics: Age Factors; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Incidence; Male; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2012 |
The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus.
Topics: Adolescent; Azathioprine; Bone Density; Bone Density Conservation Agents; Cervical Vertebrae; Diphosphonates; Female; Glucocorticoids; Humans; Imidazoles; Lupus Erythematosus, Systemic; Osteoporosis; Prednisone; Spinal Fractures; Zoledronic Acid | 2004 |